Mouse and organoid models reveal FGFR2's role in pancreatic cancer aggression and interception

Mouse and organoid models reveal FGFR2's role in pancreatic cancer aggression and interception

Pancreatic cancer is projected to become the second-deadliest cancer by 2030. By the time it's diagnosed, it's often difficult to treat. So, for both individual patients and the general population, fighting pancreatic cancer can feel like a race against time. Cold Spring Harbor Laboratory (CSHL) Professor and Cancer Center Director David Tuveson offers a telling analogy:

It is possible to slow down the growth of one of the most aggressive cancers, that of the pancreas, now a candidate to become the second killer tumor in the world by 2030. (BEND)

In pancreatic cancer, a race against time

Scientists have found a way to 'intercept' pancreatic cancer. By inhibiting the cancer gene FGFR2, they were able to slow tumor formation. By targeting the FGFR2 and EGFR proteins, they were able to prevent pancreatic cancer from forming in the first place.

David Tuveson is the director of the Cancer Research Center at Cold Spring Harbor Laboratory who, together with his team of scholars, has found a way to slow down growth...